Loading clinical trials...
Loading clinical trials...
A Phase III, Double-blind, Randomized, Placebo-controlled Multicentre Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Healthcare Professionals' Absenteeism in the SARS-CoV-2 Pandemic by Modulating the Immune System
Conditions
Interventions
VPM1002
Placebo
Locations
3
Germany
Ludwig-Maximilians-Universität München
München, Bavaria, Germany
Medizinische Hochschule Hannover
Hanover, Lower Saxony, Germany
SocraTec R&D GmbH
Erfurt, Thuringia, Germany
Start Date
May 25, 2020
Primary Completion Date
May 1, 2021
Completion Date
May 1, 2021
Last Updated
September 30, 2020
Lead Sponsor
Serum Life Science Europe GmbH
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions